Intervention not reported
Adverse events: fatigue · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: fatigue (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: rigor/chills · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: rigor/chills (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: arthralgia/myalgia · People with AML in first complete remission
It is very uncertain whether the intervention changes adverse events: arthralgia/myalgia (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life · People with AML in first complete remission
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib may leads to lower overall survival (number of deaths at compared with placebo (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with best available therapy (low certainty).
1 finding from 1 review
Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · Patients with treating MF
1 finding from 1 review
Reduction in spleen size Magnetic resonance imaging or computed tomography · Patients with treating MF
Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with best available therapy (low certainty).
1 finding from 1 review
Progression‐free survival ‐ not measured · Patients with treating MF
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · Patients with treating MF
Ruxolitinib may leads to higher safety (AE, adverse drug reaction): neutropenia Grades 3 or 4… compared with placebo (low certainty).
1 finding from 1 review
Health‐related quality of life Patients that achieved a reduction of 50% or more in the total MF Symptom Assessment Form · Patients with treating MF
Ruxolitinib may leads to higher health‐related quality of life Patients that achieved a reduction of… compared with placebo (low certainty).
1 finding from 1 review
Reduction in spleen size Magnetic resonance imaging or computed tomography · Patients with treating MF
Ruxolitinib may leads to higher reduction in spleen size Magnetic resonance imaging or computed… compared with placebo (low certainty).
1 finding from 1 review
Overall survival (number of deaths at · Patients with treating MF
Ruxolitinib showed no clear difference in overall survival (number of deaths at compared with best available therapy (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · Patients with treating MF
Ruxolitinib showed no clear difference in progression Free Survival (number of patients who had progression at compared with best available therapy (low certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): anemia Grades 3 or 4 according to National Cancer Institute · Patients with treating MF
Ruxolitinib showed no clear difference in safety (AE, adverse drug reaction): anemia Grades 3 or 4 according… compared with best available therapy (low certainty).
1 finding from 1 review
Intervention not reported
Mortality at 2 years · patients with newly diagnosed AML
The intervention leads to lower mortality at 2 years (high certainty).
1 finding from 1 review
Intervention not reported
Complete remission · patients with newly diagnosed AML
The intervention showed no clear difference in complete remission (moderate certainty).
1 finding from 1 review
Intervention not reported
Death on induction therapy · patients with newly diagnosed AML
The intervention showed no clear difference in death on induction therapy (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse · patients with newly diagnosed AML
The intervention showed no clear difference in relapse (moderate certainty).
1 finding from 1 review